Tags : Halozyme

Pharma

Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for

Shots: Halozyme will discontinue its P-III HALO-301 study evaluating PEGPH20 in combination with gemcitabine and nab-paclitaxel (Abraxane) vs gemcitabine and nab-paclitaxel as a 1L therapy for the treatment of patients with metastatic pancreatic cancer The P-III HALO-301 study results: did not meet its 1EPs of OS (11.2 vs 11.5mos.) as there was a higher response […]Read More

Biotech

Argenx Signs a Worldwide License Agreement with Halozyme for its

Shots: Halozyme to receive $30M upfront, $160M milestones, $10M per future target nominations and royalties on sales of products. Argenx to get an exclusive license for Halozyme’s ENHANZE technology targeting ARGX-113 and additional two human neonatal Fc receptors (FcRn)   The focus of this ninth agreement b/w the companies, is to develop and commercialize neonatal […]Read More